Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbactam-durlobactam in cUTI
NCT03445195Phase 2Completed
- Sponsor
- Entasis Therapeutics
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durlobactam in complicated urinary tract infection (cUTI), acute pyelonephritis, sponsored by Entasis Therapeutics. Started Jan 2018; status: completed.
02
Drugs
durlobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT03445195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445195.